-transparent.png){kind=logo}
On the basis of biopharmaceutic-pharmacokinetic and galenic aspects a new sustained-release preparation of theophylline according to the "divided-dose" principle was developed. The technological procedure used allows a reproducible manufacture of a stable product with narrow limits of pharmaceutical quality. The bioavailability of the sustained-release pellets in a dose corresponding to 350 mg active principle is examined in comparison to an aqueous solution or retard-tablet formulation on the marked (containing 260 mg drug/dose), respectively, after single or multiple dose administration to 7 healthy volunteers. The relative bioavailability of the new formulation is about 100%. During chronic application the controlled drug delivery from the sustained-release pellets warrants only slight fluctuations of plasma levels by avoiding peak concentrations. Formulations with a dosage of 200, 350 or 500 mg, respectively, allow adaptation of continuous plasma levels in the therapeutic range between 5--20 micrograms/ml according to the therapeutic necessities of a patient.
G F Schneider, and
G U Heese, and
H J Huber, and
N Janzen, and
H Jünger, and
C Moser, and
F Stanislaus
October 1979,
Annals of allergy,
G F Schneider, and
G U Heese, and
H J Huber, and
N Janzen, and
H Jünger, and
C Moser, and
F Stanislaus
October 1978,
Lijecnicki vjesnik,
G F Schneider, and
G U Heese, and
H J Huber, and
N Janzen, and
H Jünger, and
C Moser, and
F Stanislaus
November 1987,
Arerugi = [Allergy],
G F Schneider, and
G U Heese, and
H J Huber, and
N Janzen, and
H Jünger, and
C Moser, and
F Stanislaus
January 1996,
The Journal of international medical research,
G F Schneider, and
G U Heese, and
H J Huber, and
N Janzen, and
H Jünger, and
C Moser, and
F Stanislaus
January 1983,
Arzneimittel-Forschung,
G F Schneider, and
G U Heese, and
H J Huber, and
N Janzen, and
H Jünger, and
C Moser, and
F Stanislaus
January 1983,
Drug intelligence & clinical pharmacy,
G F Schneider, and
G U Heese, and
H J Huber, and
N Janzen, and
H Jünger, and
C Moser, and
F Stanislaus
May 1998,
Arzneimittel-Forschung,
G F Schneider, and
G U Heese, and
H J Huber, and
N Janzen, and
H Jünger, and
C Moser, and
F Stanislaus
January 1978,
Annals of allergy,
G F Schneider, and
G U Heese, and
H J Huber, and
N Janzen, and
H Jünger, and
C Moser, and
F Stanislaus
May 1983,
International journal of clinical pharmacology, therapy, and toxicology,
G F Schneider, and
G U Heese, and
H J Huber, and
N Janzen, and
H Jünger, and
C Moser, and
F Stanislaus
February 1983,
International journal of clinical pharmacology, therapy, and toxicology,
